NUP214 and Alzheimer disease: By introducing the LxVP peptide that interferes with CaN-NFAT binding (for exact mechanism of action see Pharmacological inhibitors of CaN/NFAT with potential use in AD treatment section) they demonstrated that systemic or local peptide delivery via adenoviral gene transfer attenuated the inflammatory response in vivo.